Drug Discovery & DDS– category –
-
Keymed Biosciences’ BCMA x CD3 Bispecific Antibody CM336 Advances to Phase II for Relapsed/Refractory Light Chain Amyloidosis, Secures $257M from Gilead’s Acquisition of Partner
BioSpace China Overview Keymed Biosciences announced its H1 2026 results and business updates, reporting that its BCMA x CD3 bispecific antibody, CM336, is progressing in a Phase II clinical trial for relapsed/refractory light chain amyl... -
FDA Grants Breakthrough Therapy and Fast Track Designations to Norroy Bioscience’s 68Ga-NYM096 for Clear Cell Renal Cell Carcinoma PET Imaging, First Chinese-Origin Radiopharmaceutical to Receive BTD
Targeted Oncology USA Overview The U.S. FDA has granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to Norroy Bioscience's investigational PET imaging agent, 68Ga-NYM096, for detecting clear cell renal cell ca... -
FDA Approves Novo Nordisk’s Pasatru for FOP, Accelerates Approval for Tudriqev Combination in Melanoma, and Greenlights mFLUSIVA mRNA Flu Vaccine
Drugs.com USA Overview In August 2026, the FDA approved several key new drugs. Novo Nordisk's Pasatru (garetosmab-grts) gained approval for adults with Fibrodysplasia Ossificans Progressiva (FOP). An accelerated approval was granted for ... -
Serina Therapeutics Highlights POZ Platform’s Potential to Enhance Efficacy and Safety of Small Molecule, RNA, and ADC Therapies
BioSpace USA Overview Serina Therapeutics announced its Q2 2026 financial and business updates, emphasizing the advancement of its wholly-owned pipeline for neurological and other indications, powered by its proprietary POZ Platform™. Th... -
Johns Hopkins Medicine Unveils Synthetic mRNA Platform for Faster, More Efficient Next-Gen Therapeutics
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have announced the development of an experimental synthetic mRNA-based platform that holds the potential to deliver next-generation mRNA therapeutics for infectious... -
Unicorn Bioscience Report: Exosome Therapy Market Valued at $58.1 Billion Despite No FDA Approvals, 240 Clinical Trials Underway
Unicorn Bioscience Unknown Overview This article provides an overview of a market research report published by Unicorn Bioscience. As of 2026, the global therapeutic exosome market is valued at $58.1 billion, a paradoxical valuation give... -
Daiichi Sankyo Leverages AI-Driven Biomarker Discovery with Tempus to Strengthen ADC Clinical Strategy
BioPharm International Japan Overview Daiichi Sankyo has announced a new partnership with AI-driven precision medicine company Tempus to enhance its antibody-drug conjugate (ADC) clinical strategy. This collaboration aims to improve pati... -
Nagoya University and Fujifilm Jointly Develop Novel LNP Delivery System for Enhanced Cyclic RNA Therapeutics
EurekAlert! Japan Overview Researchers from Nagoya University and Fujifilm have jointly developed a novel lipid nanoparticle (LNP) delivery system designed for efficient and stable intracellular delivery of circular RNA (cirRNA), a promi... -
Silence Therapeutics’ siRNA Therapeutic Divesiran Achieves 88% Response Rate in Phase II Trial for Rare Blood Cancer Polycythemia Vera
BioXconomy UK Overview Silence Therapeutics announced positive interim Phase II results from its SANRECO trial for divesiran, an siRNA therapeutic targeting polycythemia vera (PV), a rare blood cancer. The trial successfully met its prim... -
FDA Grants Accelerated Approval to BMS’s Zenbexus for Multiple Myeloma in Combination with Daratumumab
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's (BMS) Zenbexus (iberdomide), a novel CELMoD (cereblon E3 ligase modulator), for the treatment of multiple myelom...
